Investment
Features
FeesSafety
Academy
More
Pluang+

Biomerica Q1 fiscal 2027 sees 120% rise in Medicare IBS test orders, 81% OTC sales growth, but posts $1.2M net loss.

Company Fundamentals
16 Oct 2026
GlobeNewsWire
View Source
Bullish
Biomerica Q1 fiscal 2027 sees 120% rise in Medicare IBS test orders, 81% OTC sales growth, but posts $1.2M net loss.

Biomerica reported a 120% increase in Medicare-related orders for its inFoods® IBS test in September 2026, reflecting growing physician adoption and repeat usage. Over-the-counter sales rose 81% year-over-year, and cash reserves more than doubled to $2.7 million after a $2.23 million private stock placement. Despite these gains, the company posted a net loss of $1.2 million for Q1 fiscal 2027, impacted by lower gross margins and fluctuating clinical orders. Biomerica is advancing contract development projects and exploring strategic partnerships to enhance growth and shareholder value.

Biomerica's recent financial results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 16, 2026 19:01 WIB: out of 150 priced US health-sector stocks, 93 rose and 46 fell today. Notable movers include ROIV at USD 34.61 with a 1-day change of +1.67% and a typical hold time of 4 days, RVTY at USD 156.95 with +1.45% change and 13 days hold time, and ACAD at USD 19.99 with +1.42% change, where Pluang order activity was 87% Sell and 13% Buy, and a typical hold time of 77 days.

More News

Nasdaq resumes trading in CN Healthy Food Tech Group Corp. after year-long halt

Nasdaq resumes trading in CN Healthy Food Tech Group Corp. after year-long halt

Nasdaq announced that trading in CN Healthy Food Tech Group Corp.'s common stock and warrants will resume on October 19, 2026, after being halted since October 1, 2025. The resumption marks the end of a year-long trading suspension, allowing investor...

Market News
Neutral
30 minutes ago
Goldman Sachs CEO David Solomon named new chair of The Business Council, succeeding Brian Cornell.

Goldman Sachs CEO David Solomon named new chair of The Business Council, succeeding Brian Cornell.

David Solomon, CEO of Goldman Sachs, has been appointed as the new chair of The Business Council, taking over from Brian Cornell, Executive Chair of Target Corporation. This leadership change comes at a critical time as the Council addresses challeng...

Market News
Bullish
30 minutes ago
SEDA Experts appoints Noor Ul Islam as Managing Director to boost risk and securities expertise.

SEDA Experts appoints Noor Ul Islam as Managing Director to boost risk and securities expertise.

SEDA Experts LLC has appointed Noor Ul Islam as Managing Director, enhancing its capabilities in risk management and securities practices. With nearly 30 years of experience at major financial institutions like Citibank and Barclays, Islam brings dee...

Others
Neutral
30 minutes ago
Global pharmaceutical market to reach $3.22T by 2035, driven by biologics, AI drug discovery, and India’s 17.1% growth in 2026

Global pharmaceutical market to reach $3.22T by 2035, driven by biologics, AI drug discovery, and India’s 17.1% growth in 2026

The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, expanding at a CAGR of 6.15%. Growth is fueled by advances in biologics, AI-driven drug discovery, specialty drugs, and manufacturing i...

Market News
Bullish
30 minutes ago
OAAA announces winners of the 84th OBIE Awards, honoring top creative work in out of home advertising.

OAAA announces winners of the 84th OBIE Awards, honoring top creative work in out of home advertising.

The Out of Home Advertising Association of America (OAAA) held the 84th Annual OBIE Awards in New York City, celebrating the best creative campaigns in out of home (OOH) advertising. Paramount was inducted into the OBIE Hall of Fame for its longstand...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App